Baricitinib and Blood Clotting Markers in Rheumatoid Arthritis
Tests baricitinib against usual treatment in adults with rheumatoid arthritis, checking clotting and cholesterol markers.
Plain-language title generated from the registry record
Registry title: Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 4
Where in Egypt
- Tanta University HospitalsTanta, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT07357649
- Record updated
- 22 January 2026
- Original description
This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.Read full original descriptionShow less
Prospective Evaluation of Baricitinib's Effects on Procoagulant State and Atherogenic Index in Rheumatoid Arthritis Patients
This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.
Inclusion: Adults aged ≥ 18 years; Diagnosis of rheumatoid arthritis according to the ACR/EULAR 2010 criteria; Patients with active rheumatoid arthritis despite conventional treatment; Ability to provide written informed consent.
Exclusion: Dyslipidemia or use of lipid-lowering therapy within the last 6 months; Alcohol or drug abuse; Use of anticoagulant or antithrombotic drugs within the last 3 months; Presence of other autoimmune diseases; Diabetes mellitus; Chronic kidney disease; Chronic liver disease; Chronic respiratory disease; History of malignancy; Acute or chronic infection; History of arterial or venous thrombosis; Pregnancy or breastfeeding; Current prednisone dose > 7.5 mg/day.